# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.
- SEC Filing
HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.
Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $...
Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $...
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...